Nancy A. Simonian
CIK: 0001359574
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 26, 2026GENB
Generate Biomedicines, Inc.
Award(A)DirectStock Option (Right to Buy)
29.6K shares- - Dec 2, 2024SYRS
Syros Pharmaceuticals, Inc.
Sale(S)Direct37.1K shares at avg. $0.27$10K - Nov 25, 2024SYRS
Syros Pharmaceuticals, Inc.
Sale(S)Direct134.7K shares at avg. $0.27$36K - Oct 31, 2024SYRS
Syros Pharmaceuticals, Inc.
Exercise(M)Direct40.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 26, 2026 |  GENB Generate Biomedicines, Inc. | Award(A) Stock Option (Right to Buy) | 29,561 | - | - | Direct |
| Dec 2, 2024 |  SYRS Syros Pharmaceuticals, Inc. | Sale(S) | 37,070 | $0.27 | $10,016 | Direct |
| Nov 25, 2024 | SYRS Syros Pharmaceuticals, Inc. | Sale(S) | 134,713 | $0.27 | $35,739 | Direct |
| Oct 31, 2024 | SYRS Syros Pharmaceuticals, Inc. | Exercise(M) | 40,125 | - | $0 | Direct |
1-4 of 4 transactions
About Simonian Nancy A
Simonian Nancy A (SEC CIK 0001359574) files insider reports with the SEC as Director of Generate Biomedicines, Inc. (GENB) and Director of Syros Pharmaceuticals, Inc. (SYRS).
Signal8 holds 5 ownership filings by Simonian Nancy A (1 Form 3, 4 Form 4), filed between Nov 4, 2024 and Mar 2, 2026. Those filings report 4 transactions, from Oct 31, 2024 to Feb 26, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Simonian Nancy A's filings is in SOMERVILLE, MA.
Recent filings by Simonian Nancy A
Other insiders filing for Generate Biomedicines, Inc. (GENB)
- ARNOLD FRANCES, Director
- Pioneering Medicines 02, LLC, 10% Owner
- Nally Michael, Chief Executive Officer
- Vessey Rupert, Director
- Grous Beth, Chief People Officer
- Lee Laurie Anne, Chief Medical Officer